Eutilex.Co.Ltd (A263050) Stock Overview
Engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
A263050 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Eutilex.Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩959.00 |
| 52 Week High | ₩3,200.00 |
| 52 Week Low | ₩650.00 |
| Beta | 0.84 |
| 1 Month Change | 0% |
| 3 Month Change | 29.95% |
| 1 Year Change | -36.36% |
| 3 Year Change | -80.82% |
| 5 Year Change | -95.77% |
| Change since IPO | -96.32% |
Recent News & Updates
We Think Eutilex.Co.Ltd (KOSDAQ:263050) Has A Fair Chunk Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Eutilex.Co.Ltd (KOSDAQ:263050) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Recent updates
Shareholder Returns
| A263050 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 4.6% |
| 1Y | -36.4% | 33.0% | 186.6% |
Return vs Industry: A263050 underperformed the KR Biotechs industry which returned 35.8% over the past year.
Return vs Market: A263050 underperformed the KR Market which returned 158.9% over the past year.
Price Volatility
| A263050 volatility | |
|---|---|
| A263050 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in KR Market | 16.6% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A263050's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: Insufficient data to determine A263050's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Byoung-Se Kwon | www.eutilex.com |
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies.
Eutilex.Co.,Ltd Fundamentals Summary
| A263050 fundamental statistics | |
|---|---|
| Market cap | ₩35.32b |
| Earnings (TTM) | -₩23.92b |
| Revenue (TTM) | ₩10.29b |
Is A263050 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A263050 income statement (TTM) | |
|---|---|
| Revenue | ₩10.29b |
| Cost of Revenue | ₩9.89b |
| Gross Profit | ₩404.74m |
| Other Expenses | ₩24.33b |
| Earnings | -₩23.92b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -649.55 |
| Gross Margin | 3.93% |
| Net Profit Margin | -232.38% |
| Debt/Equity Ratio | 97.2% |
How did A263050 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 08:11 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eutilex.Co.,Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Taehee Kim | Mirae Asset Securities Co., Ltd. |
| Wan Ku | NH Investment & Securities Co., Ltd. |